首页> 外国专利> AQUEOUS FORMULATION FOR SELECTIVE TARGETING AND DELIVERING OF GENE TO GLUCOCORTICOID RECEPTOR EXPRESSING CANCER CELLS

AQUEOUS FORMULATION FOR SELECTIVE TARGETING AND DELIVERING OF GENE TO GLUCOCORTICOID RECEPTOR EXPRESSING CANCER CELLS

机译:用于选择性靶向和递送基因到糖皮质激素受体表达癌细胞的水制剂

摘要

Glucorticoid receptors (GR) express in various normal and cancer cells. A lot of ligand activated physiological functions are known involving GR but its role in cancer progression (if any) is not clearly understood. Synthetic GR antagonist, dexamethasone (Dex) finds use as anti-inflammatory drug and is known to induce apoptosis in cancer cells. This Dex is included in a cationic lipid-based formulation as a co-lipid to deliver to and express genes specifically in cancer cells possibly through expressed GR. Gene delivery to cancer cells is independent of the gene construct, and tumor cell line. Normal transformed cells expressing GR but with no cancer lineage show much smaller level of transfection. The composition of the formulation is optimized. The formulation may have particular application to the enhanced delivery of anticancer genetic constructs to cancer, with the synergistic effect of Dex in inducing apoptosis as such.
机译:糖皮质激素受体(GR)在各种正常细胞和癌细胞中表达。已知许多涉及GR的配体激活的生理功能,但尚不清楚其在癌症进展中的作用(如果有)。合成GR拮抗剂地塞米松(Dex)可作为抗炎药使用,并已知可诱导癌细胞凋亡。这种右旋糖酐作为一种脂质被包括在阳离子脂质基制剂中,以可能通过表达的GR传递至癌细胞并在癌细胞中特异性表达基因。向癌细胞的基因递送与基因构建体和肿瘤细胞系无关。正常表达GR的转化细胞但没有癌症谱系,其转染水平要小得多。优化了制剂的组成。该制剂可以特别用于增强抗癌基因构建体向癌症的递送,并具有Dex在诱导细胞凋亡本身方面的协同作用。

著录项

  • 公开/公告号IN261615B

    专利类型

  • 公开/公告日2014-07-04

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN1936/DEL/2006

  • 发明设计人 RAJKUMAR BANERJEE;AMARNATH MUKHERJEE;

    申请日2006-08-29

  • 分类号

  • 国家 IN

  • 入库时间 2022-08-21 15:57:16

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号